NovaBridge Biosciences (NBP) Long-Term Debt Repayments (2019 - 2020)

NovaBridge Biosciences (NBP) posted Long-Term Debt Repayments of $15.1 million for Q4 2020, down 33.53% on a QoQ basis from $22.7 million in Q4 2019, and down 33.53% YoY from $22.7 million in Q1 2020.

NovaBridge Biosciences (NBP) Long-Term Debt Repayments (2019 - 2020) Analysis & Trends

NovaBridge Biosciences (NBP) has reported Long-Term Debt Repayments for 2 consecutive years, with $15.1 million the latest figure, recorded in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -21,671.00
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 NovaBridge Biosciences 330.39 Mn 119.55 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2020 15.09 Mn
Dec 31, 2020 15.09 Mn
Dec 31, 2019 22.70 Mn
Dec 31, 2019 22.70 Mn